Survey on Anemia Therapy in Participants With Chronic Kidney Disease (CKD) Not on Dialysis
NCT ID: NCT02238067
Last Updated: 2017-03-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
196 participants
OBSERVATIONAL
2011-09-30
2013-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis
NCT02586402
Study of rESP Injection for the Treatment of Anemia in Chronic Renal Failure Patients With Hemodialysis
NCT03950687
The Clinical Evaluation of the Dose of Erythropoietins Trial
NCT00827021
Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis
NCT00112008
A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)
NCT00968617
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Chronic Renal Anemia Participants
Participants with CKD who are not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, will be interviewed by physician who will complete the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.
ESA
Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.
Satisfaction Survey Questionnaire
Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ESA
Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.
Satisfaction Survey Questionnaire
Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Treated with ESAs
* Participant is speaking the same language as the investigator interviewer
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Clalit- New Savyon Clinic
Ganey Tikva, , Israel
Clalit - Diabetic HaMoshava South Clinic
Jerusalem, , Israel
Clalit Carmiel
Karmiel, , Israel
Clalit - Professional Clinic, Zvulun
Kiryat Bialik, , Israel
Clalit Ben-Gurion
Naẕerat ‘Illit, , Israel
Kaplan Medical Center; Nephrology and Hypertension Services
Rehovot, , Israel
Clalit- Migdal HaMea Clinic, Tel Aviv
Tel Aviv, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML25473
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.